NEXANS 162.000 € (+2,21 %)
SOITEC 176.300 € (-0,59 %)
CARREFOUR 17.115 € (+0,15 %)
REMY COINTREAU 40.280 € (-0,79 %)
AIRBUS 174.260 € (+2,80 %)
CREDIT AGRICOLE 17.450 € (+1,10 %)
SES 8.895 € (-0,61 %)
UNILEVER 49.030 € (-0,60 %)
SEMCO TECHNOLOGIES 49.400 € (+1,23 %)
CATANA GROUP 2.345 € (+2,40 %)
VICAT 64.100 € (+3,72 %)
BIOSYNEX 1.170 € (+13,04 %)
RIBER 16.280 € (+5,99 %)
HAVAS 16.850 € (+2,12 %)
SMCP 5.125 € (+1,38 %)
VERALLIA 19.860 € (-1,29 %)
DBT 0.056 € (+30,23 %)
SOCIETE GENERALE 71.900 € (+4,51 %)
REXEL 37.370 € (+1,85 %)
LHYFE 2.345 € (+0,21 %)
ASML HOLDING 1 430.600 € (+1,53 %)
CAPITAL B 0.589 € (+0,10 %)
KPN KON 4.580 € (-0,89 %)
EUROCOMMERCIAL 28.750 € (+0,70 %)
ASM INTERNATIONAL 905.000 € (+0,47 %)
EUROFINS SCIENT. 63.240 € (+1,05 %)
VEOLIA ENVIRON. 35.330 € (+1,84 %)
ARCELORMITTAL SA 58.240 € (+2,57 %)
EURONEXT 145.400 € (-0,55 %)
SANOFI 77.460 € (+0,75 %)
SAINT GOBAIN 77.500 € (+2,95 %)
DANONE 61.720 € (-0,23 %)
BNP PARIBAS ACT.A 92.520 € (+2,88 %)
MEDINCELL 26.720 € (-1,69 %)
COVIVIO 54.700 € (+2,05 %)
ASR NEDERLAND 66.480 € (+1,09 %)
PHILIPS KON 23.800 € (+1,84 %)
2CRSI 49.400 € (+5,78 %)
ADYEN 987.600 € (+3,10 %)
NEXITY 8.330 € (+2,40 %)
BAM GROEP KON 9.725 € (+6,28 %)
AIR FRANCE -KLM 10.895 € (+6,24 %)
BOUYGUES 50.280 € (+1,93 %)
WOLTERS KLUWER 61.740 € (+1,35 %)
HAL TRUST 176.600 € (+0,80 %)
PLANISWARE 18.920 € (+1,61 %)
KLEA HOLDING 0.190 € (+3,49 %)
BAINS MER MONACO 133.000 € (-1,48 %)
TIKEHAU CAPITAL 17.860 € (-0,22 %)
L'OREAL 367.650 € (+1,66 %)
CAPGEMINI 104.250 € (+1,12 %)
GECINA 72.900 € (+0,76 %)
ORANGE 18.140 € (-0,36 %)
ROCTOOL 2.040 € (+17,92 %)
BE SEMICONDUCTOR 282.000 € (+3,07 %)
LVMH 477.900 € (+1,12 %)
STMICROELECTRONICS 58.020 € (+0,16 %)
EKINOPS 3.415 € (+10,16 %)
VERIMATRIX 0.205 € (+12,64 %)
PROSUS 40.155 € (+2,80 %) |
12/05/2026 07:00
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.MindMaze Therapeutics Holding SA / Key word(s): Partnership MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S. Geneva, Switzerland and Mechanicsburg, Pennsylvania – May 12, 2026 – MindMaze Therapeutics, a pioneer in advanced neurotherapeutic technologies, and Vibra Healthcare, a leading provider of neurological care and rehabilitation services, today announced the signing of a definitive channel partnership agreement. The agreement follows the previously announced term sheet and formalizes Vibra’s role as a strategic commercial partner to introduce MindMaze Therapeutics’ FDA-cleared digital neurotherapeutics platform to leading U.S. health systems. “This next phase of our collaboration with Vibra is a significant step in MindMaze Therapeutics’ U.S. commercial expansion. Vibra has successfully implemented our platform across multiple care settings, and together we have demonstrated the results and built the operational playbook. We are now positioned to replicate that proven model with health systems across the country and further build our U.S. footprint,” said Zach Henderson, CEO of MindMaze Therapeutics. Under the agreement, Vibra will leverage its national relationships and operational credibility to connect MindMaze Therapeutics with providers investing in advanced neurorehabilitation capabilities. The commercial model is anchored by Vibra’s own two-year, multi-site deployment of the MindMaze Therapeutics platform across five inpatient rehabilitation centers, which demonstrated that the high-dose, high-intensity therapy recommended by guidelines can be operationalized at scale without increasing staffing burden. “Vibra entered this relationship because we saw a genuine opportunity to change what’s possible in neurorehabilitation,” said Brad Hollinger, Chairman and CEO of Vibra Healthcare. “What we’ve built with MindMaze Therapeutics is a scalable model that leading rehabilitation providers should aspire to offer. We look forward to bringing it to health system partners across the country.” Providers adopting the platform gain a scalable solution that enables clinicians to treat more patients at a higher level of care with the same resources, supports shorter inpatient lengths of stay, improves community discharge rates, and delivers consistent therapy intensity across the full continuum of care. MindMaze Therapeutics expects the Vibra partnership to be a key driver of new U.S. health system customer acquisition in the second half of 2026 and beyond. About Vibra Healthcare About MindMaze Therapeutics Media Contacts DISCLAIMER Additional features: File: Ad hoc release_MindMaze-Vibra_Definitive Channel Partnership End of Inside Information
2325694 12-May-2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière